ABBOTT LABORATORIES (ABT) Company Report

Abbott posted Q4 adjusted EPS of $1.50, roughly in line with expectations, but revenue of $11.46 – 11.50 billion fell short and shares closed down 10% on the day.
Nutrition sales declined ~9% to $1.9 billion, driven by promotions and lost volume after price hikes, contributing heavily to the revenue shortfall.
Management guided Q1 adjusted EPS of $1.12–1.18 versus a $1.19 Street consensus, and full-year targets for 6.5%–7.5% organic sales growth and $5.55–5.80 adjusted EPS.
Abbott expects its $21 billion Exact Sciences acquisition to close in Q2 2026, aiming to strengthen its diagnostics business.

Jan 22, 2026, 9:13 PM

Bloomberg

Abbott reports Q4 2025 earnings

ABT

Earnings

Guidance Update

M&A

Abbott delivered adjusted diluted EPS of $1.50 in Q4 2025, a 12% decline year-over-year, and full-year EPS of $5.15, down 10% YoY.
Fourth-quarter sales by segment were $5.7 B in Medical Devices, $2.5 B in Diagnostics, $1.9 B in Nutrition and $1.4 B in Established Pharmaceuticals.
The company issued FY 2026 guidance of 6.5%–7.5% organic sales growth and $5.55–$5.80 adjusted EPS.
Abbott agreed to acquire Exact Sciences, entering the ~$60 B U.S. cancer screening and precision oncology diagnostics market.
The quarterly dividend was raised 6.8% to $0.63 per share for 2026, marking 54 consecutive years of increases.

Jan 22, 2026, 2:00 PM

Presentation

Abbott reports Q4 2025 results

ABT

Earnings

Guidance Update

M&A

In 2025, Abbott delivered top-tier margin expansion and achieved double-digit EPS growth despite tariffs and China challenges, and announced the acquisition of Exact Sciences to enter the cancer diagnostics market.
Q4 results included organic sales growth of 3.8% ex-COVID, adjusted EPS of $1.50 (+12%), adjusted gross margin of 57.1% (+20 bps), and adjusted operating margin of 25.8% (+150 bps).
Segment highlights: Nutrition sales declined; Diagnostics sales down 3.5% (Core Lab +3.5%, Point-of-Care +7%); Emerging Products & Technologies +7%; Medical Devices +10.5% (CGM sales +12% Q4, +17% FY to >$7.5 billion).
2026 guidance: organic sales growth of 6.5–7.5%, FX tailwind ~1%; adjusted EPS of $5.55–5.80 (Q1 EPS $1.12–1.18); tax rate of 15–16%.

Jan 22, 2026, 2:00 PM

Transcript

Abbott Laboratories announces Q4 2025 results

ABT

Earnings

Guidance Update

M&A

Nutrition sales declined on U.S. pediatric market-share loss; company is implementing price and promotion initiatives to reignite volume growth, with headwinds in H1 2026 and recovery expected in H2 2026.
Diagnostics Q4 sales fell 3.5% due to lower COVID test volumes; Core Lab Diagnostics grew 3.5% in Q4 (7% FY ex-China), point-of-care +7%; EPD +7%; Medical Devices +10.5%, driven by CGM growth of 12% Q4 and 17% FY (>$7.5 billion).
Q4 organic sales increased 3.8% ex-COVID, and adjusted EPS was $1.50, up 12% YoY.
2026 outlook: organic sales growth of 6.5–7.5%, adjusted EPS of $5.55–5.80 (+10% at midpoint), Q1 EPS of $1.12–1.18, FX tailwind ~1% on sales, and an adjusted tax rate of 15–16%.
Announced acquisition of Exact Sciences to enter the cancer diagnostics market, adding a ~$3 billion high-growth business and pipeline.

Jan 22, 2026, 2:00 PM

Transcript

Abbott reports Q4 2025 results and 2026 guidance

ABT

Earnings

Guidance Update

M&A

Abbott’s Q4 2025 organic sales excluding COVID testing grew 3.8% and adjusted EPS was $1.50, up 12% year-over-year.
For full-year 2026, Abbott forecasts 6.5%–7.5% organic sales growth (midpoint 7%) and adjusted EPS of $5.55–$5.80 (midpoint 10% growth), with Q1 EPS of $1.12–$1.18.
Nutrition sales declined in Q4 due to higher pricing and loss of market share; the company has launched price and promotion initiatives and expects H1 2026 headwinds with a return to growth in H2 2026.
Diagnostics saw a 3.5% sales decline driven by lower COVID testing, while Core Lab Diagnostics grew 3.5% in Q4 (7% for FY ex-China) and point-of-care diagnostics rose 7%.
Medical devices sales rose 10.5% in Q4, led by continuous glucose monitoring (+12% Q4; +17% FY, > $7.5 billion sales), plus robust growth across electrophysiology, structural heart, heart failure, rhythm management, vascular and neuromodulation.
Abbott announced the acquisition of Exact Sciences to enter the cancer diagnostics market with a high-growth, ~$3 billion business and attractive pipeline.

Jan 22, 2026, 2:00 PM

Transcript

Abbott reports Q4 and full-year 2025 results and issues 2026 outlook

ABT

Earnings

Guidance Update

M&A

Q4 GAAP diluted EPS was $1.01, and adjusted diluted EPS was $1.50 (+12%).
Q4 sales grew 4.4% reported, 3.0% organic, or 3.8% excluding COVID-19 testing.
FY 2025 sales were $44.3 billion (+5.7% reported, +5.5% organic), with GAAP EPS of $3.72 and adjusted EPS of $5.15 (+10%).
For 2026, Abbott forecasts organic sales growth of 6.5%–7.5% and adjusted diluted EPS of $5.55–$5.80 (+10% at midpoint).
Abbott agreed to acquire Exact Sciences to enter the cancer diagnostics market, expected to close in Q2 2026.

Jan 22, 2026, 12:35 PM

8-K

Abbott reports Q4 and full-year 2025 results and 2026 outlook

ABT

Earnings

Guidance Update

M&A

Fourth-quarter sales increased 4.4% reported (3.0% organic); GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.50 (+12%)
Full-year 2025 sales of $44.3 billion (+5.7% reported, 5.5% organic); GAAP diluted EPS of $3.72, adjusted EPS of $5.15 (+10%)
2026 guidance: organic sales growth of 6.5%–7.5% and adjusted diluted EPS of $5.55–$5.80 (10% growth at midpoint)
Agreed to acquire Exact Sciences, expected to close in Q2 2026
Declared $0.63 quarterly dividend, payable Feb. 13, 2026

Jan 22, 2026, 12:30 PM

Press Release

Abbott receives CE Mark for TactiFlex Duo Ablation Catheter

ABT

Product Launch

Abbott has received CE Mark in Europe for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled, to treat atrial fibrillation patients with complex cases.
The catheter features dual-energy delivery, allowing both radiofrequency and pulsed field ablation (PFA) during a single procedure.
The first successful commercial cases using TactiFlex Duo in the European Union were completed this week.
CE Mark approval was supported by data from the global FOCALFLEX CE Mark study demonstrating clinically meaningful safety and effectiveness outcomes in AFib patients.
This approval is Abbott’s third significant PFA approval in under a year, following Volt PFA System approvals in the U.S. and Europe in 2025.

Jan 20, 2026, 2:00 PM

Press Release

Abbott Laboratories receives FDA approval for Volt Afib system

ABT

Product Launch

Revenue Acceleration/Inflection

The FDA approved Abbott’s over-the-wire Volt Pulsed Field Ablation (PFA) System for treating atrial fibrillation after its CE mark in March, with U.S. commercial cases set to begin soon.
The pivotal VOLT-AF IDE trial enrolled 392 patients across 40 centers in the U.S., Europe, Canada and Australia, meeting key safety and effectiveness endpoints for both paroxysmal and persistent AFib.
Volt integrates with Abbott’s EnSite X mapping platform and uses a balloon-in-basket catheter to map, pace and ablate in one device, enabling procedures under conscious sedation.
CEO Robert Ford said Abbott’s electrophysiology segment is experiencing double-digit growth, and he expects Volt to be a major growth driver for the cardiology business in 2026.

Dec 22, 2025, 2:21 PM

Morningstar

Abbott receives FDA approval for Volt PFA System to treat AFib

ABT

Product Launch

Abbott’s Volt PFA System has received FDA approval for treating atrial fibrillation in the U.S., with commercial cases to begin soon.
Approval is based on the VOLT-AF IDE study of 392 patients at 40 centers, demonstrating strong safety and effectiveness in both paroxysmal and persistent AFib.
The all-in-one system features real-time contact visualization, shorter procedure times, conscious sedation options, reduced radiation exposure and integration with the EnSite™ X EP System.

Dec 22, 2025, 2:00 PM

Press Release